Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 8, 2011, Pages 1029-1031

  Civallero, Monica ^a   Cosenza, Maria ^a   Bari, Alessia ^a   Sacchi, Stefano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

B NHL; Combined therapies; Enzastaurin; Signaling pathway inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAL 101; CARFILZOMIB; CD20 ANTIBODY; ENZASTAURIN; EVEROLIMUS; FOSTAMATINIB; LENALIDOMIDE; MOCETINOSTAT; NAVITOCLAX; PANOBINOSTAT; PCI 32765; PERIFOSINE; PROTEASOME INHIBITOR; PROTEIN KINASE C BETA; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; ROMIDEPSIN; SB 1518; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VORINOSTAT;

CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG MECHANISM; HUMAN; IMMUNOTHERAPY; LARGE CELL CARCINOMA; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; INDOLES; LYMPHOMA, B-CELL; MOLECULAR TARGETED THERAPY; THALIDOMIDE;

EID: 79960341257     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.594793     Document Type: Review

References (25)

1. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469-76 (Pubitemid 351559319)
2. Sacchi S, Pozzi S, Marcheselli L, et al. Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077-82 (Pubitemid 46744202)
3. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d?Etoudes des Lymphomes de l?Adulte. Blood 2010;20:2040-5
4. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology (Am Soc Hematol Educ Program) 2010;2010:265-70
5. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-84 (Pubitemid 41348658)
6. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74 (Pubitemid 34101731)
7. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9 (Pubitemid 41161281)
8. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 2007;109:1669-77 (Pubitemid 46239601)
9. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374-83 (Pubitemid 352015802)
10. Kuo WL, Liu J, Mauceri H, et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signalling context. Mol Cancer Ther 2010;9:2814-24
11. Civallero M, Cosenza M, Neri A, et al. Genomic profiling of enzastaurin treated B cell lymphoma RL cells. Hematol Oncol 2010; Epub ahead of print]
12. Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 2009;27:23-30
13. Civallero M, Cosenza M, Grisendi G, et al.Effects of Enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 2010;51:671-9
14. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor Enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72 (Pubitemid 46827795)
15. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of Enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9 (Pubitemid 46622284)
16. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of Enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6 (Pubitemid 46797955)
17. Schwartzberg L, Hermann RC, Flinnet IW, et al. Enzastaurin in patients with follicular lymphoma: results of a phase II study abstract]. J Clin Oncol 2010;28(15S):8040
18. Gobrial IM, Harousseau JL, Treon SP, et al. Enzastaurin in previously treated Waldenstrom's Macroglobulinemia: an open-label, multicenter, phase II study abstract]. Blood 2009;114:3867
19. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of Enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53 (Pubitemid 351209293)
20. Ysebaert I, Morschhauser F. Enzastaurin hydrochloride for lymphoma. Exp Opin Invest Drugs 2011;20(8):1167-74
21. Teeling JL, French RR, Cregg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800 (Pubitemid 39202289)
22. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
23. Sacchi S, Marcheselli R, Bari A, et al. Phase II study of Velcade- plus Mabthera- in relapsed follicular lymphomas abstract]. Blood 2010;116:1801
24. Fowler NH, McLaughlin P, Hagemeister FB.complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma abstract]. J Clin Oncol 2010;28(15S):8036
25. Sacchi S, Cosenza M, Civallero M, et al.combination of enzastaurin, a PKC inhibitor, and revlimid ®has synergistic activity in non-hodgkin lymphoma abstract]. Blood 2010;116:4905